BSD Announces the Opening of the Center for Treatment of Children with Hyperthermia and Chemotherapy at Charité UMS

German Joint Health Insurance Funds Reimburse Quality Controlled Pediatric Hyperthermia Treatments of Solid Tumors

This is the Second German Center Established for the Treatment of Pediatric Tumors

SALT LAKE CITY--()--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Charité Universitätsmedizin Berlin (Charité), Department of Pediatric Hematology and Oncology, in cooperation with the Charité Department of Radiation Oncology, has opened a center dedicated to the treatment of pediatric tumors using hyperthermia and chemotherapy. Prof. Angelika Eggert MD, Chair of the Department of Pediatric Hematology and Oncology as well as President of the German Society of Pediatric Hematology and Oncology, and Prof. Volker Budach MD, Chair of the Department of Radiation Oncology, will oversee the center. The German Joint Health Insurance Funds reimburse quality controlled pediatric hyperthermia treatments of solid tumors. The quality control parameters have been set and were published in Strahlentherapie & Onkologie in 2012 by the IAH Interdisziplinäre Arbeitsgruppe für Hyperthermie (Interdisciplinary Working Group for Hyperthermia) of DEGRO (Deutsche Gesellschaft für Radioonkologie), which is the German Society for Radiation Oncology.

“Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.”

The pediatric cancer treatment center was opened as a result of the very positive published results of the UMS Dusseldorf study on the use of hyperthermia (delivered using the BSD-2000 Hyperthermia System), combined with chemotherapy and tumor resection, to treat malignant germ cell tumors in children and adolescents. (Wessalowski et al. “Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.” The Lancet Oncology, 2013.) The published study demonstrated an objective tumor reduction in 86% of the patients, with a 5-year overall survival rate of 72% (95% CI 55-83) and a 5-year event-free survival of 62% (95% CI 45-75), which is unmatched by any other clinical report on recurrent childhood malignant germ-cell tumors.

This is the second center that has opened in Germany dedicated to the treatment of pediatric tumors using hyperthermia and chemotherapy. The Paediatric Oncology Clinic, Haematology and Immunology, Centre for Child and Adolescent Health, Heinrich-Heine University, Dusseldorf was the first center.

About Charité - Universitätsmedizin Berlin

The Charité - Universitätsmedizin Berlin (Charité) is one of the largest university hospitals in Europe and employs 3700 doctors and scientists. Charite is an international leader in oncology research and medical training. More than half of the German Nobel Prize winners in medicine and physiology come from the Charité. The Charité extends over four campuses with almost 100 clinics and institutes bundled under 17 Charité Centers.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused microwave energy and radiofrequency (RF). BSD’s product lines include ablation and hyperthermia treatment systems. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and well established distribution in the United States, Europe and Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our 2014 plans, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the market demand for our MicroThermX® products and the regulatory requirements we face. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.

Contacts

for BSD Medical Corporation
Tricia Ross
310-622-8226
tross@finprofiles.com

BSD Medical Corporation